论文部分内容阅读
目的 探讨氟哌啶醇合并托吡酯治疗难治性Tourette综合征(TS)的临床疗效和安全性。方法 将65例难治性TS患儿按病例编号分为试验组(33例)和对照组(32例)。试验组给予氟哌啶醇合并托吡酯治疗,对照组采取常规治疗[单一或联合使用氟哌啶醇(6-14mg／d)、泰必利(300-600mg／d)、安定类药物],共治疗8周。采用YGTSS、国际TS临床信息调查表、儿童行为量表(CBCL)及副反应量表(TESS),于治疗后第1、4、8周末对两组进行评估。结果 治疗第8周末,试验组的有效率为96％,高于对照组68％(P<0.01);试验组YGTSS总分低于对照组(P<0.01),减分率高于对照组(P<0.01);试验组的CBCL评分低于对照组(P<0.01);从第4周末开始试验组TESS评分低于对照组(P<0.05),并持续至第8周末(P<0.01)。结论 氟哌啶醇合并托吡酯治疗难治性TS,疗效肯定,副反应相对较轻。
Objective To investigate the clinical efficacy and safety of haloperidol combined with topiramate in the treatment of Tourette’s syndrome (TS). Methods 65 cases of refractory TS were divided into experimental group (33 cases) and control group (32 cases) by case number. The trial group was treated with haloperidol combined with topiramate, and the control group was treated with conventional therapy (single or combined haloperidol (6-14mg / d), tiapride (300-600mg / d), diazepam) Treatment for 8 weeks. The YGTSS, the International TS Clinical Information Questionnaire, the Child Behavior Scale (CBCL) and the TESS were used to assess the two groups at the end of the 1st, 4th, and 8th week after treatment. Results At the end of the 8th week, the effective rate of the experimental group was 96%, which was higher than that of the control group (P <0.01). The total score of YGTSS in the experimental group was lower than that of the control group (P <0.01) (P <0.01). The CBCL score of the experimental group was lower than that of the control group (P <0.01). The TESS score of the experimental group was lower than that of the control group from the 4th weekend (P <0.05) . Conclusion Haloperidol combined with topiramate in the treatment of refractory TS, positive effect, side effects are relatively mild.